St Jude's "thinnest" implantable cardioverter defibrillator lead:
This article was originally published in Clinica
Executive Summary
St Jude Medical has received US FDA approval to sell what it claims is the world's thinnest implantable cardioverter defibrillator (ICD) lead. The Riata ST 6.3F lead has an "ultra-thin diameter", making it easier for doctors to handle the device and to position it precisely at the cardiac site, said the St Paul, Minnesota firm. It preserves venous space, an important consideration when treating patients with implantable devices, especially those with pre-existing or multiple lead systems, as it minimises restriction to blood flow. Riata ST is thinner than previous versions of St Jude's Riata ICD lead family.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.